CJC-1295: frequently asked questions, answered from the record

What CJC-1295 is and how it acts

These cover the basics — definition, mechanism, classification, and the forms. Where a number appears, it is tagged to the study that measured it; where the honest answer is that the data do not exist, the answer says so. This page is the full index of the questions readers ask; the topic pages carry the same answers in context.

What is CJC-1295?

A synthetic long-acting analog of growth-hormone-releasing hormone (GHRH), built on hGRF(1-29) with four protease-resistant substitutions ^[2]. The DAC variant adds covalent albumin conjugation for a multi-day half-life ^[1]; the no-DAC form, "Modified GRF (1-29)," keeps the substitutions but is short-acting.

What does CJC-1295 do?

It binds the GHRH receptor on pituitary somatotrophs to stimulate growth-hormone release, which raises hepatic IGF-1 ^[2]. In healthy adults, single doses produced dose-dependent multi-day GH and IGF-1 elevations ^[1][3] while preserving the natural pulsatile pattern of GH secretion.

Is CJC-1295 a steroid?

No. CJC-1295 is a peptide GHRH analog that acts on the GHRH receptor to stimulate the body's own growth-hormone release ^[2]. It is not an anabolic-androgenic steroid and works through an entirely different pathway — the GH/IGF-1 axis rather than the androgen receptor.

Does CJC-1295 affect sleep?

GHRH administration enhanced slow-wave sleep and nocturnal GH secretion in normal men, linking GHRH-axis stimulation to sleep architecture ^[6], and a 2025 study mapped a sleep-dependent GH-release circuit ^[11]. CJC-1295 itself has not been studied directly for sleep endpoints, so any sleep effect is inferred from the axis it acts on, not measured for the compound.

What is CJC-1295 with DAC?

The DAC ("Drug Affinity Complex") variant carries a maleimidopropionyl linker that covalently binds serum albumin at Cys34, extending plasma half-life toward that of albumin — an estimated 5.8-8.1 days in healthy adults ^[1][2]. The albumin tether is what makes it the long-acting form.

What is CJC-1295 DAC?

CJC-1295 DAC is the albumin-conjugated, long-acting form of the tetrasubstituted GHRH(1-29) analog. In rats it produced a 4-fold GH AUC over the unconjugated peptide and was detectable in plasma beyond 72 hours ^[2]. It is the species responsible for the multi-day duration.

Dosage, handling, and the ipamorelin pairing

Every answer here reports research parameters or handling notes from the published record. None is a recommendation, a protocol, or a dose to take — there is no approved human dose for CJC-1295.

How much CJC-1295 should I take?

Published human PK studies used single subcutaneous doses of 30, 60, or 90 µg/kg ^[1][3]. There is no approved human dose; community fixed-dose protocols are not derived from controlled trials. This site reports study doses as research parameters, not as a recommendation to take any amount.

How much CJC-1295 DAC should I take?

Human PK data for the DAC form come from single-dose studies of 30-90 µg/kg; a single dose elevated GH and IGF-1 for days, with an estimated half-life of 5.8-8.1 days ^[1]. No approved human dosing exists, so no quantity is recommended here.

How much CJC-1295 / ipamorelin should I take?

There is no controlled-trial human dose for the CJC-1295/ipamorelin combination. The pairing rationale is mechanistic — a GHRH analog plus a selective GH secretagogue acting on different receptors — and ipamorelin was characterized as the first highly selective GH secretagogue ^[4]. Community microgram protocols are not trial-derived.

How to reconstitute CJC-1295?

In research handling it is supplied as a lyophilized peptide, reconstituted with bacteriostatic water, and refrigerated. Oral bioavailability is negligible because the peptide is degraded in the gut, so subcutaneous injection is the route used in studies ^[1][2]. These are handling notes, not instructions for use.

Where to inject CJC-1295?

All human and animal CJC-1295 studies used subcutaneous injection; early GRF(1-29) PK work also used the intravenous route ^[1][2]. The compound is not orally bioavailable, so injection is the only route the literature characterizes. The studies do not standardize specific sites.

What is CJC-1295 ipamorelin?

It refers to combining CJC-1295 (a GHRH analog) with ipamorelin (a selective GH secretagogue, or GHRP). The two stimulate growth-hormone release through complementary receptors — the GHRH receptor and the ghrelin/GHS receptor — which is the basis for studying them together ^[4].

Does CJC-1295 and ipamorelin work?

The combination rests on the two-receptor model: GHRH analogs and GHRPs act through distinct receptors and synergize on GH release ^[4]. The mechanistic rationale is solid, but controlled human efficacy data for this specific pairing are limited, so "works" is supported as a mechanism more than as a trial outcome.

What to expect when taking CJC-1295?

In healthy-adult studies a single dose raised mean GH several-fold for days and IGF-1 for nine to eleven days while preserving pulsatile GH secretion ^[1][3]. These are pharmacokinetic and pharmacodynamic observations in early studies, not clinical outcomes such as body-composition or performance endpoints, and they are not a guide to personal use.

What does the literature note about CJC-1295 side effects?

CJC-1295 is an unapproved research chemical, and the safety answers below come from a limited human record plus the known biology of the GH/IGF-1 axis. The reported concerns are inferred from GH-axis biology and IGF-1 epidemiology, not measured in large dedicated CJC-1295 safety trials, because no such trials exist.

Is CJC-1295 safe?

CJC-1295 is an unapproved research chemical with limited human data. Sustained GH/IGF-1 elevation raises theoretical concerns — fluid retention, effects on insulin sensitivity, and epidemiology linking higher IGF-1 to modestly increased risk of certain cancers ^[14] — and FDA briefing materials cited immunogenicity. Safety has not been established in controlled trials.

Are CJC-1295 peptides safe?

Human safety data are limited to early pharmacokinetic studies ^[1][3]. Theoretical concerns include fluid retention, effects on insulin sensitivity, and IGF-1/cancer epidemiology ^[14]. It remains an unapproved research compound with no large efficacy or long-term safety trials in healthy adults.

What are the side effects of CJC-1295?

GH-axis stimulation can cause fluid retention and edema because GH promotes renal sodium reabsorption, and it may affect insulin sensitivity; FDA materials also cited immunogenicity concerns. These effects are inferred from GH-axis biology, not measured in large dedicated CJC-1295 safety trials.

Is CJC-1295 FDA approved?

No. CJC-1295 is not approved for human use by the FDA or any major regulator; it is handled as a research chemical. It was reviewed at the 2024 FDA Pharmacy Compounding Advisory Committee and was not recommended for the 503A compounding bulks list. It is also prohibited at all times in sport under WADA Section S2.

The testosterone questions

A recurring cluster of searches asks whether CJC-1295 changes testosterone. The short answer across all of them: it acts on the growth-hormone axis, not the gonadal axis, and the published record reports no direct testosterone effect either way.

Does CJC affect testosterone?

CJC-1295 acts on the GH/IGF-1 axis, not the gonadal axis. The published literature does not report direct testosterone changes from CJC-1295, and any claims to that effect are not supported by controlled human data — the compound's measured effects are on GH and IGF-1.

Does CJC-1295 affect testosterone?

CJC-1295 acts on the GH/IGF-1 axis, not the hypothalamic-pituitary-gonadal axis that governs testosterone. The published CJC-1295 literature does not report direct testosterone changes in either direction, and claims to that effect are not supported by controlled human data — the measured effects are on growth hormone and IGF-1 ^[1][3].

Does CJC-1295 lower testosterone?

There is no controlled human evidence that CJC-1295 lowers testosterone. It operates on the growth-hormone axis rather than the hypothalamic-pituitary-gonadal axis, and no published CJC-1295 study reports a testosterone decrease; a suppressive effect on androgens is not something the literature documents for this compound.

Does CJC-1295 raise testosterone?

No published CJC-1295 study reports a testosterone increase. Its measured effects are on GH and IGF-1 ^[1][3], not on androgens, so a testosterone rise is not supported by the literature; sources that market it as a testosterone booster are not citing controlled CJC-1295 data.

Are peptides safer than TRT?

This is not answerable from the CJC-1295 literature. Testosterone replacement is an approved therapy with decades of data, whereas CJC-1295 is an unapproved GH-axis peptide with limited human evidence, so any safety comparison between the two would be speculative rather than evidence-based.